[
  {
    "slug": "aicar",
    "identifiers": {
      "unii": "F0X88YW0YK",
      "cas": "3031-94-5",
      "verified": "2026-08-17"
    },
    "name": "AICAR",
    "aliases": [
      "Acadesine"
    ],
    "class": "Adenosine analogue and AMPK activator, a natural purine intermediate, not a peptide",
    "eu_status": "unclear",
    "evidence_tier": "B",
    "legal_flags": {
      "de": {
        "status": "doping_classified",
        "basis": "DmMV 2023 Anlage (BGBl 2023 I Nr. 67), heading III, Hormon- und Stoffwechsel-Modulatoren, category AMPK (PPAR-delta-AMP-activated protein kinase)-Axis-Agonisten, names AICAR among its examples.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38335 rows; semaglutid, tirzepatid, somatropin, afamelanotid resolve). Lag (1991:1969) 1 § names no peptide and we do not apply it. Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": "2025-06",
    "last_verified": "2026-08-15"
  },
  {
    "slug": "alexamorelin",
    "name": "Alexamorelin",
    "aliases": [],
    "class": "Synthetic heptapeptide growth hormone secretagogue",
    "eu_status": "unclear",
    "evidence_tier": "B",
    "legal_flags": {
      "de": {
        "status": "unclear",
        "basis": "Not named in the DmMV 2023 Anlage (BGBl 2023 I Nr. 67), checked at source with four positive controls found. Its GHRP and GH-secretagogue categories are both headed Zum Beispiel, so absence from the printed examples does not place a compound outside a category. Neither is applied here.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38336 rows; semaglutid, tirzepatid, somatropin, afamelanotid resolve). Lag (1991:1969) 1 § names no peptide and we do not apply it. Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": "2011-02",
    "last_verified": "2026-08-17"
  },
  {
    "slug": "amycretin",
    "name": "Amycretin",
    "aliases": [],
    "class": "Unimolecular GLP-1 and amylin receptor agonist",
    "eu_status": "unclear",
    "evidence_tier": "B",
    "legal_flags": {
      "de": {
        "status": "unclear",
        "basis": "Amycretin does not appear in the DmMV 2023 Anlage, checked by full-text search across all headings on 2026-08-15. German medicines law under AMG §§ 73, 96, 97 is a separate question and is not established here.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38335 rows; semaglutid, tirzepatid, somatropin, afamelanotid resolve). Lag (1991:1969) 1 § names no peptide and we do not apply it. Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": null,
    "last_verified": "2026-08-15"
  },
  {
    "slug": "anamorelin",
    "identifiers": {
      "unii": "DD5RBA1NKF",
      "cas": "249921-19-5",
      "verified": "2026-08-17"
    },
    "name": "Anamorelin",
    "aliases": [
      "Adlumiz"
    ],
    "class": "Growth hormone secretagogue receptor 1a agonist, an orally active ghrelin mimetic",
    "eu_status": "unauthorised",
    "evidence_tier": "A",
    "legal_flags": {
      "de": {
        "status": "doping_classified",
        "basis": "DmMV 2023 Anlage (BGBl 2023 I Nr. 67), heading II, category Wachstumshormon Sekretagoge (GHS) und ihre Mimetika, names Anamorelin among its examples.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38336 rows; semaglutid, tirzepatid, somatropin, teriparatid all resolve). Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": null,
    "last_verified": "2026-08-17"
  },
  {
    "slug": "aod-9604",
    "identifiers": {
      "unii": "7UP768IP4M",
      "cas": "221231-10-3",
      "verified": "2026-08-17"
    },
    "name": "AOD-9604",
    "aliases": [
      "AOD9604",
      "AOD 9604",
      "LAT-8881",
      "LAT8881"
    ],
    "class": "Synthetic analogue of the lipolytic domain of human growth hormone",
    "eu_status": "unclear",
    "evidence_tier": "B",
    "legal_flags": {
      "de": {
        "status": "doping_classified",
        "basis": "DmMV 2023 Anlage (BGBl 2023 I Nr. 67), heading II, category Wachstumshormon-Fragmente, names AOD-9604 and hGH-Fragment 176-191 among its examples.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Not in Lakemedelsverket's product register (Lakemedelsprodukter.xlsx, 38335 rows, extracted 2026-08-15, updated daily); semaglutid, tirzepatid, somatropin and afamelanotid all resolve in it. Lag (1991:1969) 1 § names no peptide and we do not apply it to a compound.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": "2013-09",
    "last_verified": "2026-08-15"
  },
  {
    "slug": "bpc-157",
    "identifiers": {
      "unii": "8ED8NXK95P",
      "cas": "137525-51-0",
      "verified": "2026-08-17"
    },
    "name": "BPC-157",
    "aliases": [
      "Body protecting compound 157",
      "Bepecin",
      "PCO-02"
    ],
    "class": "Synthetic pentadecapeptide derived from a human gastric juice protein sequence",
    "eu_status": "unclear",
    "evidence_tier": "B",
    "legal_flags": {
      "de": {
        "status": "unclear",
        "basis": "Not named in the DmMV 2023 Anlage (BGBl 2023 I Nr. 67), checked against the recorded heading II table. Those categories are headed Zum Beispiel, so absence from the printed examples does not place a compound outside its category.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38336 rows; semaglutid, somatropin, teriparatid all resolve). Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": "2017-02",
    "last_verified": "2026-08-17"
  },
  {
    "slug": "brp",
    "name": "BRP",
    "aliases": [
      "BRINP2-related peptide"
    ],
    "class": "12-mer peptide derived from BRINP2 by prohormone convertase cleavage",
    "eu_status": "unclear",
    "evidence_tier": "C",
    "legal_flags": {
      "de": {
        "status": "unclear",
        "basis": "BRP and BRINP2-related peptide do not appear in the DmMV 2023 Anlage, checked by full-text search across all headings on 2026-08-15. German medicines law under AMG §§ 73, 96, 97 is a separate question and is not established here.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38335 rows; semaglutid, tirzepatid, somatropin, afamelanotid resolve). Lag (1991:1969) 1 § names no peptide and we do not apply it. Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": null,
    "last_verified": "2026-08-15"
  },
  {
    "slug": "cagrilintide",
    "identifiers": {
      "unii": "AO43BIF1U8",
      "cas": "1415456-99-3",
      "verified": "2026-08-17"
    },
    "name": "Cagrilintide",
    "aliases": [],
    "class": "Long-acting amylin analogue",
    "eu_status": "investigational",
    "evidence_tier": "B",
    "legal_flags": {
      "de": {
        "status": "unclear",
        "basis": "Cagrilintide does not appear in the DmMV 2023 Anlage, checked by full-text search across all headings on 2026-08-15. German medicines law under AMG §§ 73, 96, 97 is a separate question and is not established here.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38335 rows; semaglutid, tirzepatid, somatropin, afamelanotid resolve). Lag (1991:1969) 1 § names no peptide and we do not apply it. Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": null,
    "last_verified": "2026-08-15"
  },
  {
    "slug": "cjc-1295",
    "identifiers": {
      "unii": "62RC32V9N7",
      "cas": "446262-90-4",
      "verified": "2026-08-17"
    },
    "name": "CJC-1295",
    "aliases": [
      "CJC1295",
      "CJC 1295",
      "CJC-1295 DAC"
    ],
    "class": "Tetrasubstituted hGRF(1-29) with a C-terminal maleimidopropionamide-lysine that binds albumin",
    "eu_status": "unclear",
    "evidence_tier": "B",
    "legal_flags": {
      "de": {
        "status": "doping_classified",
        "basis": "DmMV 2023 Anlage (BGBl 2023 I Nr. 67), heading II, category Wachstumshormon Releasingfaktoren, names CJC-1295 and mod-GRF among its examples.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38335 rows; semaglutid, tirzepatid, somatropin, afamelanotid resolve). Lag (1991:1969) 1 § names no peptide and we do not apply it. Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": "2010-11",
    "last_verified": "2026-08-17"
  },
  {
    "slug": "ct-388",
    "identifiers": {
      "unii": "MTP9QR7GYF",
      "cas": "2869147-44-2",
      "verified": "2026-08-17"
    },
    "name": "Enicepatide",
    "aliases": [
      "CT-388",
      "RO7795068"
    ],
    "class": "Synthetic peptide",
    "eu_status": "investigational",
    "evidence_tier": "B",
    "legal_flags": {
      "de": {
        "status": "unclear",
        "basis": "CT-388 does not appear in the DmMV 2023 Anlage, checked by full-text search across all headings on 2026-08-15. German medicines law under AMG §§ 73, 96, 97 is a separate question and is not established here.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38335 rows; semaglutid, tirzepatid, somatropin, afamelanotid resolve). Lag (1991:1969) 1 § names no peptide and we do not apply it. Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": null,
    "last_verified": "2026-08-15"
  },
  {
    "slug": "dihexa",
    "identifiers": {
      "unii": "9WYX65A5C2",
      "cas": "1401708-83-5",
      "verified": "2026-08-17"
    },
    "name": "Dihexa",
    "aliases": [
      "N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide"
    ],
    "class": "Synthetic angiotensin IV analogue",
    "eu_status": "unclear",
    "evidence_tier": "C",
    "legal_flags": {
      "de": {
        "status": "unclear",
        "basis": "Dihexa does not appear in the DmMV 2023 Anlage, checked by full-text search on 2026-08-15. German medicines law under AMG §§ 73, 96, 97 is a separate question and is not established here.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38335 rows; semaglutid, tirzepatid, somatropin, afamelanotid resolve). Lag (1991:1969) 1 § names no peptide and we do not apply it. Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": "2024-09",
    "last_verified": "2026-08-15"
  },
  {
    "slug": "dsip",
    "identifiers": {
      "unii": "YN28Z5YZ73",
      "cas": "62568-57-4",
      "verified": "2026-08-17"
    },
    "name": "DSIP",
    "aliases": [
      "delta sleep-inducing peptide",
      "emideltide"
    ],
    "class": "Synthetic nonapeptide, the delta sleep-inducing peptide",
    "eu_status": "unclear",
    "evidence_tier": "B",
    "legal_flags": {
      "de": {
        "status": "unclear",
        "basis": "DSIP, Delta-Schlaf and Emideltid do not appear in the DmMV 2023 Anlage, checked by full-text search on 2026-08-15. German medicines law under AMG §§ 73, 96, 97 is a separate question and is not established here.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38335 rows; semaglutid, tirzepatid, somatropin, afamelanotid resolve). Lag (1991:1969) 1 § names no peptide and we do not apply it. Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": null,
    "last_verified": "2026-08-15"
  },
  {
    "slug": "eloralintide",
    "identifiers": {
      "unii": "73G3354J8W",
      "cas": "2883634-40-8",
      "verified": "2026-08-17"
    },
    "name": "Eloralintide",
    "aliases": [
      "LY3841136"
    ],
    "class": "Selective amylin receptor agonist",
    "eu_status": "investigational",
    "evidence_tier": "B",
    "legal_flags": {
      "de": {
        "status": "unclear",
        "basis": "Eloralintide does not appear in the DmMV 2023 Anlage, checked by full-text search across all headings on 2026-08-15. German medicines law under AMG §§ 73, 96, 97 is a separate question and is not established here.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38335 rows; semaglutid, tirzepatid, somatropin, afamelanotid resolve). Lag (1991:1969) 1 § names no peptide and we do not apply it. Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": null,
    "last_verified": "2026-08-15"
  },
  {
    "slug": "epitalon",
    "identifiers": {
      "unii": "O65P17785G",
      "cas": "307297-39-8",
      "verified": "2026-08-17"
    },
    "name": "Epitalon",
    "aliases": [
      "Epithalon",
      "Epithalone"
    ],
    "class": "Synthetic tetrapeptide, Ala-Glu-Asp-Gly",
    "eu_status": "unclear",
    "evidence_tier": "B",
    "legal_flags": {
      "de": {
        "status": "unclear",
        "basis": "Epitalon and epithalon do not appear anywhere in the DmMV 2023 Anlage, checked by full-text search across all headings on 2026-08-15. German medicines law under AMG §§ 73, 96, 97 is a separate question and is not established here.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38335 rows; semaglutid, tirzepatid, somatropin, afamelanotid resolve). Lag (1991:1969) 1 § names no peptide and we do not apply it. Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": null,
    "last_verified": "2026-08-15"
  },
  {
    "slug": "follistatin-344",
    "name": "Follistatin 344",
    "aliases": [
      "FS344",
      "follistatin-344"
    ],
    "class": "Myostatin-inhibiting protein",
    "eu_status": "unclear",
    "evidence_tier": "B",
    "legal_flags": {
      "de": {
        "status": "doping_classified",
        "basis": "DmMV 2023 Anlage (BGBl 2023 I Nr. 67), heading III, Hormon- und Stoffwechsel-Modulatoren, category Myostatinfunktionen verandernde Stoffe, names Follistatin und seine Derivate.",
        "verified": "2026-08-15"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38335 rows; semaglutid, tirzepatid, somatropin, afamelanotid resolve). Lag (1991:1969) 1 § names no peptide and we do not apply it. Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": "2019-11",
    "last_verified": "2026-08-15"
  },
  {
    "slug": "ghk-cu",
    "identifiers": {
      "unii": "6BJQ43T1I9",
      "cas": "89030-95-5",
      "verified": "2026-08-17"
    },
    "name": "GHK-Cu",
    "aliases": [
      "copper tripeptide-1",
      "GHK copper",
      "prezatide copper",
      "glycyl-L-histidyl-L-lysine copper"
    ],
    "class": "Copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine",
    "eu_status": "unclear",
    "evidence_tier": "B",
    "legal_flags": {
      "de": {
        "status": "unclear",
        "basis": "GHK, glycyl-histidyl-lysine and copper tripeptide do not appear in the DmMV 2023 Anlage, checked by full-text search on 2026-08-15. German medicines law under AMG §§ 73, 96, 97 is a separate question and is not established here.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38335 rows; semaglutid, tirzepatid, somatropin, afamelanotid resolve). Lag (1991:1969) 1 § names no peptide and we do not apply it. Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": null,
    "last_verified": "2026-08-15"
  },
  {
    "slug": "ghrp-2",
    "identifiers": {
      "unii": "E6S6E1F19M",
      "cas": "158861-67-7",
      "verified": "2026-08-17"
    },
    "name": "GHRP-2",
    "aliases": [
      "Pralmorelin",
      "GHRP2",
      "GHRP 2"
    ],
    "class": "Synthetic growth hormone-releasing peptide, a growth hormone secretagogue",
    "eu_status": "unclear",
    "evidence_tier": "B",
    "legal_flags": {
      "de": {
        "status": "doping_classified",
        "basis": "DmMV 2023 Anlage (BGBl 2023 I Nr. 67), heading II, category Peptide mit gleicher Wirkung wie Wachstumshormon Releasingfaktoren (GHRP), names GHRP-2, synonym Pralmorelin, among its examples.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38335 rows; semaglutid, tirzepatid, somatropin, afamelanotid resolve). Lag (1991:1969) 1 § names no peptide and we do not apply it. Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": "2010-03",
    "last_verified": "2026-08-15"
  },
  {
    "slug": "ghrp-2-gly",
    "name": "GHRP-2-Gly",
    "aliases": [
      "Gly-GHRP-2"
    ],
    "class": "GHRP-2 extended by an N-terminal glycine residue",
    "eu_status": "unclear",
    "evidence_tier": "D",
    "legal_flags": {
      "de": {
        "status": "doping_classified",
        "basis": "DmMV 2023 Anlage (BGBl 2023 I Nr. 67), heading II, category Peptide mit gleicher Wirkung wie Wachstumshormon Releasingfaktoren (GHRP), names GHRP-2-Gly among its examples.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38336 rows; semaglutid, somatropin, teriparatid all resolve). Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": "2018-05",
    "last_verified": "2026-08-17"
  },
  {
    "slug": "ghrp-6",
    "identifiers": {
      "unii": "4H7N4I6X6A",
      "cas": "87616-84-0",
      "verified": "2026-08-17"
    },
    "name": "GHRP-6",
    "aliases": [
      "GHRP6",
      "GHRP 6",
      "Hexapeptide-2",
      "SKF-110679",
      "U-75799E"
    ],
    "class": "Synthetic growth hormone-releasing hexapeptide",
    "eu_status": "unclear",
    "evidence_tier": "B",
    "legal_flags": {
      "de": {
        "status": "doping_classified",
        "basis": "DmMV 2023 Anlage (BGBl 2023 I Nr. 67), heading II, category Peptide mit gleicher Wirkung wie Wachstumshormon Releasingfaktoren (GHRP), names GHRP-6 among its examples.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38335 rows; semaglutid, tirzepatid, somatropin, afamelanotid resolve). Lag (1991:1969) 1 § names no peptide and we do not apply it. Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": "2011-02",
    "last_verified": "2026-08-15"
  },
  {
    "slug": "ghrp-6-gly",
    "name": "GHRP-6-Gly",
    "aliases": [
      "Gly-GHRP-6"
    ],
    "class": "GHRP-6 extended by an N-terminal glycine residue",
    "eu_status": "unclear",
    "evidence_tier": "D",
    "legal_flags": {
      "de": {
        "status": "doping_classified",
        "basis": "DmMV 2023 Anlage (BGBl 2023 I Nr. 67), heading II, category Peptide mit gleicher Wirkung wie Wachstumshormon Releasingfaktoren (GHRP), names GHRP-6-Gly among its examples.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38336 rows; semaglutid, somatropin, teriparatid all resolve). Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": "2018-05",
    "last_verified": "2026-08-17"
  },
  {
    "slug": "hexarelin",
    "identifiers": {
      "unii": "09QF37C617",
      "cas": "140703-51-1",
      "verified": "2026-08-17"
    },
    "name": "Hexarelin",
    "aliases": [
      "Examorelin",
      "EP-23905",
      "MF-6003"
    ],
    "class": "Synthetic hexapeptide growth hormone-releasing peptide, an analogue of GHRP-6",
    "eu_status": "unclear",
    "evidence_tier": "B",
    "legal_flags": {
      "de": {
        "status": "doping_classified",
        "basis": "DmMV 2023 Anlage (BGBl 2023 I Nr. 67), heading II, category Peptide mit gleicher Wirkung wie Wachstumshormon Releasingfaktoren (GHRP), names Hexarelin among its examples.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38335 rows; semaglutid, tirzepatid, somatropin, afamelanotid resolve). Lag (1991:1969) 1 § names no peptide and we do not apply it. Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": "2011-02",
    "last_verified": "2026-08-15"
  },
  {
    "slug": "hgh-fragment-176-191",
    "name": "hGH Fragment 176-191",
    "aliases": [
      "HGH Frag 176-191",
      "Frag 176-191",
      "hGH 176-191",
      "growth hormone fragment 176-191"
    ],
    "class": "Synthetic peptide of amino acids 176-191 of the C-terminus of human growth hormone",
    "eu_status": "unclear",
    "evidence_tier": "C",
    "legal_flags": {
      "de": {
        "status": "doping_classified",
        "basis": "DmMV 2023 Anlage (BGBl 2023 I Nr. 67), heading II, category Wachstumshormon-Fragmente, names hGH-Fragment 176-191 among its examples, separately from AOD-9604.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38335 rows; semaglutid, tirzepatid, somatropin, afamelanotid resolve). Lag (1991:1969) 1 § names no peptide and we do not apply it. Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": "2026-03",
    "last_verified": "2026-08-15"
  },
  {
    "slug": "ipamorelin",
    "identifiers": {
      "unii": "Y9M3S784Z6",
      "cas": "170851-70-4",
      "verified": "2026-08-17"
    },
    "name": "Ipamorelin",
    "aliases": [
      "NNC 26-0161"
    ],
    "class": "Growth hormone secretagogue receptor 1a agonist, a ghrelin mimetic",
    "eu_status": "unclear",
    "evidence_tier": "B",
    "legal_flags": {
      "de": {
        "status": "doping_classified",
        "basis": "DmMV 2023 Anlage (BGBl 2023 I Nr. 67), heading II, category Wachstumshormon-Sekretagoge (GHS) und ihre Mimetika, names Ipamorelin among its examples.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38335 rows; semaglutid, tirzepatid, somatropin, afamelanotid resolve). Lag (1991:1969) 1 § names no peptide and we do not apply it. Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": "2011-02",
    "last_verified": "2026-08-15"
  },
  {
    "slug": "kpv",
    "name": "KPV",
    "aliases": [
      "alpha-MSH(11-13)"
    ],
    "class": "COOH-terminal tripeptide of alpha-melanocyte-stimulating hormone",
    "eu_status": "unclear",
    "evidence_tier": "C",
    "legal_flags": {
      "de": {
        "status": "unclear",
        "basis": "KPV does not appear in the DmMV 2023 Anlage, checked by full-text search on 2026-08-15. German medicines law under AMG §§ 73, 96, 97 is a separate question and is not established here.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38335 rows; semaglutid, tirzepatid, somatropin, afamelanotid resolve). Lag (1991:1969) 1 § names no peptide and we do not apply it. Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": null,
    "last_verified": "2026-08-15"
  },
  {
    "slug": "lenomorelin",
    "identifiers": {
      "unii": "UXG268Q86R",
      "cas": "258279-04-8",
      "verified": "2026-08-17"
    },
    "name": "Lenomorelin",
    "aliases": [
      "Ghrelin",
      "Acyl-ghrelin"
    ],
    "class": "Endogenous growth hormone secretagogue receptor 1a agonist, 28 residues",
    "eu_status": "investigational",
    "evidence_tier": "B",
    "legal_flags": {
      "de": {
        "status": "doping_classified",
        "basis": "DmMV 2023 Anlage (BGBl 2023 I Nr. 67), heading II, category Wachstumshormon Sekretagoge (GHS) und ihre Mimetika, names Lenomorelin (Ghrelin) among its examples.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38336 rows; semaglutid, somatropin, teriparatid all resolve). Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": null,
    "last_verified": "2026-08-17"
  },
  {
    "slug": "ll-37",
    "identifiers": {
      "unii": "3DD771JO2H",
      "cas": "154947-66-7",
      "verified": "2026-08-17"
    },
    "name": "LL-37",
    "aliases": [
      "cathelicidin LL-37",
      "Ropocamptide"
    ],
    "class": "Antimicrobial peptide produced by cleavage of the human cathelicidin hCAP-18",
    "eu_status": "investigational",
    "evidence_tier": "B",
    "legal_flags": {
      "de": {
        "status": "unclear",
        "basis": "LL-37 and Cathelicidin do not appear in the DmMV 2023 Anlage, checked by full-text search on 2026-08-15. German medicines law under AMG §§ 73, 96, 97 is a separate question and is not established here.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38335 rows; semaglutid, tirzepatid, somatropin, afamelanotid resolve). Lag (1991:1969) 1 § names no peptide and we do not apply it. Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": "2019-09",
    "last_verified": "2026-08-24"
  },
  {
    "slug": "longr3-igf-1",
    "identifiers": {
      "unii": "M9L22Y19H9",
      "cas": "143045-27-6",
      "verified": "2026-08-17"
    },
    "name": "LongR3-IGF-1",
    "aliases": [
      "IGF-1 LR3",
      "Long R3 insulin-like growth factor-I",
      "Long-(Arg3)insulin-like growth factor-I"
    ],
    "class": "IGF-1 analogue with arginine at position 3 and a 13-residue N-terminal extension",
    "eu_status": "unclear",
    "evidence_tier": "C",
    "legal_flags": {
      "de": {
        "status": "unclear",
        "basis": "DmMV 2023 Anlage (BGBl 2023 I Nr. 67), category Wachstumsfaktoren und Wachstumsfaktor- Modulatoren, carries a line IGF-1 Analoga which names no examples. Whether a compound falls inside a statutory category is a legal judgement, so the texts are set side by side and neither is applied.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38335 rows; somatropin and mekasermin resolve). Lag (1991:1969) 1 § names no peptide and we do not apply it. Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": "2021-02",
    "last_verified": "2026-08-17"
  },
  {
    "slug": "macimorelin",
    "identifiers": {
      "unii": "8680B21W73",
      "cas": "381231-18-1",
      "verified": "2026-08-17"
    },
    "name": "Macimorelin",
    "aliases": [
      "Ghryvelin",
      "Macimorelin Aeterna Zentaris"
    ],
    "class": "Growth hormone secretagogue receptor 1a agonist, an orally active ghrelin mimetic",
    "eu_status": "authorised",
    "evidence_tier": "A",
    "legal_flags": {
      "de": {
        "status": "doping_classified",
        "basis": "DmMV 2023 Anlage (BGBl 2023 I Nr. 67), heading II, category Wachstumshormon Sekretagoge (GHS) und ihre Mimetika, names Macimorelin among its examples. Being an authorised medicine does not remove a substance from the Anlage; both records are stated and neither is applied.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "authorised",
        "basis": "Lakemedelsprodukter.xlsx holds GHRYVELIN, 60 mg, granulat till oral suspension i dospase, ATC V04CD06, Verksamt amne macimorelinacetat, Registrerings-status Godkand.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": null,
    "last_verified": "2026-08-17"
  },
  {
    "slug": "mazdutide",
    "identifiers": {
      "unii": "MB76Z4IBZ5",
      "cas": "2259884-03-0",
      "verified": "2026-08-25"
    },
    "name": "Mazdutide",
    "aliases": [
      "IBI362",
      "IBI-362",
      "LY-3305677",
      "LY3305677"
    ],
    "class": "GLP-1 and glucagon receptor dual agonist",
    "eu_status": "unclear",
    "evidence_tier": "B",
    "legal_flags": {
      "de": {
        "status": "unclear",
        "basis": "Mazdutide does not appear in the DmMV 2023 Anlage, checked by full-text search across all headings on 2026-08-15. German medicines law under AMG §§ 73, 96, 97 is a separate question and is not established here.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38335 rows; semaglutid, tirzepatid, somatropin, afamelanotid resolve). Lag (1991:1969) 1 § names no peptide and we do not apply it. Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": null,
    "last_verified": "2026-08-15"
  },
  {
    "slug": "mecasermin",
    "identifiers": {
      "unii": "7GR9I2683O",
      "verified": "2026-08-17"
    },
    "name": "Mecasermin",
    "aliases": [
      "Increlex",
      "Mekasermin",
      "Insulin-like Growth Factor-1"
    ],
    "class": "Recombinant human insulin-like growth factor 1 (rhIGF-1)",
    "eu_status": "authorised",
    "evidence_tier": "A",
    "legal_flags": {
      "de": {
        "status": "doping_classified",
        "basis": "DmMV 2023 Anlage (BGBl 2023 I Nr. 67), category Wachstumsfaktoren und Wachstumsfaktor- Modulatoren, names Mecasermin directly as a substance with the synonym Insulin-like Growth Factor-1, not as an example under Zum Beispiel. Being an authorised medicine does not remove a substance from the Anlage.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "authorised",
        "basis": "Lakemedelsprodukter.xlsx holds INCRELEX, 10 mg/ml injektionsvatska, ATC H01AC03, Verksamt amne mekasermin, Registrerings-status Godkand, Receptbelagt, EUMA-nummer EU/1/07/402. Note the Swedish spelling mekasermin; a search on mecasermin returns zero.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": null,
    "last_verified": "2026-08-17"
  },
  {
    "slug": "melanotan-2",
    "identifiers": {
      "unii": "UPF5CJ93X7",
      "cas": "121062-08-6",
      "verified": "2026-08-17"
    },
    "name": "Melanotan 2",
    "aliases": [
      "MT-II",
      "MT2",
      "Melanotan II",
      "melanotan II"
    ],
    "class": "Synthetic cyclic analogue of alpha-melanocyte stimulating hormone",
    "eu_status": "unclear",
    "evidence_tier": "B",
    "legal_flags": {
      "de": {
        "status": "unclear",
        "basis": "Melanotan does not appear in the DmMV 2023 Anlage, checked by full-text search on 2026-08-15. German medicines law under AMG §§ 73, 96, 97 is a separate question and is not established here.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unauthorised_medicine",
        "basis": "Lakemedelsverket states \"Melanotan 2 ar olagligt att salja och marknadsfora i Sverige\" - sale and marketing, not possession or use, and we do not extend it. Corroborated: absent from Lakemedelsprodukter.xlsx, 38335 rows, 2026-08-15.",
        "verified": "2026-08-15"
      }
    },
    "first_observed": "2009-02",
    "last_verified": "2026-08-15"
  },
  {
    "slug": "mk-677",
    "identifiers": {
      "unii": "GJ0EGN38UL",
      "cas": "159634-47-6",
      "verified": "2026-08-17"
    },
    "name": "Ibutamoren",
    "aliases": [
      "MK-677",
      "MK-0677",
      "MK 677",
      "L-163,191",
      "ibutamoren mesylate",
      "Nutrabol"
    ],
    "class": "Orally active non-peptide growth hormone secretagogue and ghrelin receptor (GHSR1a) agonist",
    "eu_status": "investigational",
    "evidence_tier": "B",
    "legal_flags": {
      "de": {
        "status": "doping_classified",
        "basis": "DmMV 2023 Anlage (BGBl 2023 I Nr. 67), heading II, category Wachstumshormon-Sekretagoge (GHS) und ihre Mimetika, names Ibutamoren (MK-677) among its examples.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38335 rows; semaglutid, tirzepatid, somatropin, afamelanotid resolve). Lag (1991:1969) 1 § names no peptide and we do not apply it. Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": "2016-08",
    "last_verified": "2026-08-15"
  },
  {
    "slug": "mod-grf-1-29",
    "name": "Modified GRF 1-29",
    "aliases": [
      "mod-GRF",
      "mod-GRF 1-29",
      "CJC-1295 without DAC",
      "modified growth hormone releasing factor"
    ],
    "class": "Analogue of human growth hormone-releasing factor 1-29 without the drug affinity complex",
    "eu_status": "unclear",
    "evidence_tier": "D",
    "legal_flags": {
      "de": {
        "status": "doping_classified",
        "basis": "DmMV 2023 Anlage (BGBl 2023 I Nr. 67), heading II, category Wachstumshormon Releasingfaktoren, names mod-GRF among its examples, separately from CJC-1295.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38335 rows; semaglutid, tirzepatid, somatropin, afamelanotid resolve). Lag (1991:1969) 1 § names no peptide and we do not apply it. Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": null,
    "last_verified": "2026-08-15"
  },
  {
    "slug": "mots-c",
    "identifiers": {
      "unii": "A5CV6JFB78",
      "cas": "1627580-64-6",
      "verified": "2026-08-17"
    },
    "name": "MOTS-c",
    "aliases": [
      "MOTs-C"
    ],
    "class": "Mitochondrial-derived peptide",
    "eu_status": "unclear",
    "evidence_tier": "C",
    "legal_flags": {
      "de": {
        "status": "unclear",
        "basis": "MOTS-c does not appear anywhere in the DmMV 2023 Anlage, checked by full-text search across all headings on 2026-08-15. German medicines law under AMG §§ 73, 96, 97 is a separate question and is not established here.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38335 rows; semaglutid, tirzepatid, somatropin, afamelanotid resolve). Lag (1991:1969) 1 § names no peptide and we do not apply it. Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": null,
    "last_verified": "2026-08-15"
  },
  {
    "slug": "orforglipron",
    "identifiers": {
      "unii": "7ZW40D021M",
      "cas": "2212020-52-3",
      "verified": "2026-08-17"
    },
    "name": "Orforglipron",
    "aliases": [
      "LY3502970"
    ],
    "class": "Oral non-peptide glucagon-like peptide-1 receptor agonist",
    "eu_status": "investigational",
    "evidence_tier": "A",
    "legal_flags": {
      "de": {
        "status": "unclear",
        "basis": "Orforglipron does not appear in the DmMV 2023 Anlage, checked by full-text search across all headings on 2026-08-15. German medicines law under AMG §§ 73, 96, 97 is a separate question and is not established here.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38335 rows; semaglutid, tirzepatid, somatropin, afamelanotid resolve). Lag (1991:1969) 1 § names no peptide and we do not apply it. Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": null,
    "last_verified": "2026-08-15"
  },
  {
    "slug": "peg-mgf",
    "name": "PEG-MGF",
    "aliases": [
      "pegylated mechano growth factor"
    ],
    "class": "Pegylated form of mechano growth factor, a splice variant of IGF-1",
    "eu_status": "unclear",
    "evidence_tier": "D",
    "legal_flags": {
      "de": {
        "status": "unclear",
        "basis": "The DmMV 2023 Anlage names the category Mechano Growth Factor (MGF) und MGF-Varianten and gives no examples for it. Whether PEG-MGF falls inside that category is a legal judgement and is not made here. Read 2026-08-15.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38335 rows; semaglutid, tirzepatid, somatropin, afamelanotid resolve). Lag (1991:1969) 1 § names no peptide and we do not apply it. Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": null,
    "last_verified": "2026-08-15"
  },
  {
    "slug": "pemvidutide",
    "identifiers": {
      "unii": "A35F525WBG",
      "cas": "2538014-94-5",
      "verified": "2026-08-17"
    },
    "name": "Pemvidutide",
    "aliases": [],
    "class": "GLP-1 and glucagon dual receptor agonist",
    "eu_status": "unclear",
    "evidence_tier": "B",
    "legal_flags": {
      "de": {
        "status": "unclear",
        "basis": "Pemvidutide does not appear in the DmMV 2023 Anlage, checked by full-text search across all headings on 2026-08-15. German medicines law under AMG §§ 73, 96, 97 is a separate question and is not established here.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38335 rows; semaglutid, tirzepatid, somatropin, afamelanotid resolve). Lag (1991:1969) 1 § names no peptide and we do not apply it. Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": null,
    "last_verified": "2026-08-15"
  },
  {
    "slug": "petrelintide",
    "identifiers": {
      "unii": "D78KBY7BRU",
      "cas": "2766385-23-1",
      "verified": "2026-08-17"
    },
    "name": "Petrelintide",
    "aliases": [
      "ZP-8396",
      "ZP8396"
    ],
    "class": "36-residue peptide",
    "eu_status": "investigational",
    "evidence_tier": "B",
    "legal_flags": {
      "de": {
        "status": "unclear",
        "basis": "Petrelintide does not appear in the DmMV 2023 Anlage, checked by full-text search across all headings on 2026-08-15. German medicines law under AMG §§ 73, 96, 97 is a separate question and is not established here.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38335 rows; semaglutid, tirzepatid, somatropin, afamelanotid resolve). Lag (1991:1969) 1 § names no peptide and we do not apply it. Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": null,
    "last_verified": "2026-08-15"
  },
  {
    "slug": "pt-141",
    "identifiers": {
      "unii": "6Y24O4F92S",
      "cas": "189691-06-3",
      "verified": "2026-08-17"
    },
    "name": "Bremelanotide",
    "aliases": [
      "PT-141",
      "PT 141",
      "Vyleesi"
    ],
    "class": "Synthetic melanocortin receptor agonist",
    "eu_status": "unclear",
    "evidence_tier": "A",
    "legal_flags": {
      "de": {
        "status": "unclear",
        "basis": "Bremelanotide and PT-141 do not appear in the DmMV 2023 Anlage, checked by full-text search on 2026-08-15. German medicines law under AMG §§ 73, 96, 97 is a separate question and is not established here.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38335 rows; semaglutid, tirzepatid, somatropin, afamelanotid resolve). Lag (1991:1969) 1 § names no peptide and we do not apply it. Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": "2019-06",
    "last_verified": "2026-08-15"
  },
  {
    "slug": "retatrutide",
    "identifiers": {
      "unii": "NOP2Y096GV",
      "cas": "2381089-83-2",
      "verified": "2026-09-02"
    },
    "name": "Retatrutide",
    "aliases": [
      "LY3437943",
      "LY-3437943"
    ],
    "class": "GIP, GLP-1 and glucagon receptor triple agonist",
    "eu_status": "investigational",
    "evidence_tier": "unclear",
    "legal_flags": {
      "de": {
        "status": "unclear",
        "basis": "This record makes no German legal classification. EU regulatory status is recorded separately.",
        "verified": "2026-09-02"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from the Swedish medicines agency product register Lakemedelsprodukter.xlsx (38415 rows on 2026-09-02; semaglutid, tirzepatid, somatropin and afamelanotid all resolve, retatrutid does not). Absence from a product register does not settle regulatory status.",
        "verified": "2026-09-02"
      }
    },
    "first_observed": "2026-04",
    "last_verified": "2026-09-02"
  },
  {
    "slug": "selank",
    "identifiers": {
      "unii": "TS9JR8EP1G",
      "cas": "129954-34-3",
      "verified": "2026-08-17"
    },
    "name": "Selank",
    "aliases": [
      "TP-7",
      "selank acetate"
    ],
    "class": "Synthetic analogue of the immunomodulatory peptide tuftsin",
    "eu_status": "unclear",
    "evidence_tier": "B",
    "legal_flags": {
      "de": {
        "status": "unclear",
        "basis": "Selank does not appear in the DmMV 2023 Anlage, checked by full-text search on 2026-08-15. German medicines law under AMG §§ 73, 96, 97 is a separate question and is not established here.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38335 rows; semaglutid, tirzepatid, somatropin, afamelanotid resolve). Lag (1991:1969) 1 § names no peptide and we do not apply it. Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": null,
    "last_verified": "2026-08-15"
  },
  {
    "slug": "semax",
    "identifiers": {
      "unii": "I5FAL2585H",
      "cas": "80714-61-0",
      "verified": "2026-08-17"
    },
    "name": "Semax",
    "aliases": [],
    "class": "Synthetic heptapeptide derivative of ACTH(4-10)",
    "eu_status": "unclear",
    "evidence_tier": "B",
    "legal_flags": {
      "de": {
        "status": "unclear",
        "basis": "Semax does not appear in the DmMV 2023 Anlage, checked by full-text search on 2026-08-15. German medicines law under AMG §§ 73, 96, 97 is a separate question and is not established here.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38335 rows; semaglutid, tirzepatid, somatropin, afamelanotid resolve). Lag (1991:1969) 1 § names no peptide and we do not apply it. Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": null,
    "last_verified": "2026-08-15"
  },
  {
    "slug": "sermorelin",
    "identifiers": {
      "unii": "89243S03TE",
      "cas": "86168-78-7",
      "verified": "2026-08-17"
    },
    "name": "Sermorelin",
    "aliases": [
      "GHRH (1-29)",
      "Geref"
    ],
    "class": "Growth hormone-releasing hormone analogue, the first 29 residues of GHRH",
    "eu_status": "unclear",
    "evidence_tier": "B",
    "legal_flags": {
      "de": {
        "status": "doping_classified",
        "basis": "DmMV 2023 Anlage (BGBl 2023 I Nr. 67), heading II, category Wachstumshormon Releasingfaktoren (GHRH), names Sermorelin among its examples.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Lakemedelsprodukter.xlsx holds Geref, 50 mikrogram, ATC V04CD03, Verksamt amne sermorelin, Registrerings-status Avregistrerad. A deregistered product is not a current authorisation, and deregistration is not a prohibition.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": null,
    "last_verified": "2026-08-17"
  },
  {
    "slug": "somatorelin",
    "identifiers": {
      "unii": "4UR7N9Z9MM",
      "cas": "9034-39-3",
      "verified": "2026-08-17"
    },
    "name": "Somatorelin",
    "aliases": [
      "GHRH (1-44)",
      "GHRF",
      "Esfarase"
    ],
    "class": "Growth hormone-releasing hormone, the full 44-residue sequence",
    "eu_status": "unclear",
    "evidence_tier": "B",
    "legal_flags": {
      "de": {
        "status": "doping_classified",
        "basis": "DmMV 2023 Anlage (BGBl 2023 I Nr. 67), heading II, category Wachstumshormon Releasingfaktoren (GHRH), names Somatorelin among its examples.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38336 rows; semaglutid, somatropin, teriparatid all resolve). Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": null,
    "last_verified": "2026-08-17"
  },
  {
    "slug": "stamulumab",
    "identifiers": {
      "unii": "V43X8G4797",
      "cas": "705287-60-1",
      "verified": "2026-08-17"
    },
    "name": "Stamulumab",
    "aliases": [
      "MYO-029"
    ],
    "class": "Neutralising antibody to myostatin (GDF-8)",
    "eu_status": "unclear",
    "evidence_tier": "B",
    "legal_flags": {
      "de": {
        "status": "doping_classified",
        "basis": "DmMV 2023 Anlage (BGBl 2023 I Nr. 67), category Myostatinfunktionen verandernde Stoffe, names Stamulumab directly as a substance and not as an example under Zum Beispiel.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38335 rows; somatropin and mekasermin resolve; myostatin also returns nothing). Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": null,
    "last_verified": "2026-08-17"
  },
  {
    "slug": "survodutide",
    "identifiers": {
      "unii": "2ALA66NS64",
      "cas": "2805997-46-8",
      "verified": "2026-08-17"
    },
    "name": "Survodutide",
    "aliases": [],
    "class": "Dual glucagon and GLP-1 receptor agonist",
    "eu_status": "investigational",
    "evidence_tier": "B",
    "legal_flags": {
      "de": {
        "status": "unclear",
        "basis": "Survodutide does not appear in the DmMV 2023 Anlage, checked by full-text search across all headings on 2026-08-15. German medicines law under AMG §§ 73, 96, 97 is a separate question and is not established here.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38335 rows; semaglutid, tirzepatid, somatropin, afamelanotid resolve). Lag (1991:1969) 1 § names no peptide and we do not apply it. Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": null,
    "last_verified": "2026-08-15"
  },
  {
    "slug": "tabimorelin",
    "identifiers": {
      "unii": "L51CBE03KF",
      "cas": "193079-69-5",
      "verified": "2026-08-17"
    },
    "name": "Tabimorelin",
    "aliases": [
      "NN703"
    ],
    "class": "Growth hormone secretagogue receptor 1a agonist, an orally active ghrelin mimetic",
    "eu_status": "unclear",
    "evidence_tier": "B",
    "legal_flags": {
      "de": {
        "status": "doping_classified",
        "basis": "DmMV 2023 Anlage (BGBl 2023 I Nr. 67), heading II, category Wachstumshormon Sekretagoge (GHS) und ihre Mimetika, names Tabimorelin among its examples.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38336 rows; semaglutid, tirzepatid, somatropin, teriparatid all resolve). Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": null,
    "last_verified": "2026-08-17"
  },
  {
    "slug": "tb-500",
    "identifiers": {
      "unii": "QHK6Z47GTG",
      "cas": "885340-08-9",
      "verified": "2026-08-17"
    },
    "name": "TB-500",
    "aliases": [
      "TB500",
      "TB 500",
      "thymosin beta-4 fragment 17-23",
      "Ac-LKKTETQ"
    ],
    "class": "N-terminal acetylated 17-23 fragment of thymosin beta-4",
    "eu_status": "unclear",
    "evidence_tier": "C",
    "legal_flags": {
      "de": {
        "status": "doping_classified",
        "basis": "DmMV 2023 Anlage (BGBl 2023 I Nr. 67), heading II, category Thymosin-beta-4 und seine Derivate, names TB-500 among its examples.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38335 rows; semaglutid, tirzepatid, somatropin, afamelanotid resolve). Lag (1991:1969) 1 § names no peptide and we do not apply it. Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": "2012-09",
    "last_verified": "2026-08-15"
  },
  {
    "slug": "tesamorelin",
    "identifiers": {
      "unii": "MQG94M5EEO",
      "cas": "218949-48-5",
      "verified": "2026-08-17"
    },
    "name": "Tesamorelin",
    "aliases": [
      "Egrifta"
    ],
    "class": "Synthetic analogue of human growth hormone-releasing factor",
    "eu_status": "unclear",
    "evidence_tier": "A",
    "legal_flags": {
      "de": {
        "status": "doping_classified",
        "basis": "DmMV 2023 Anlage (BGBl 2023 I Nr. 67), heading II, category Wachstumshormon Releasingfaktoren, names Tesamorelin among its examples.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38335 rows; semaglutid, tirzepatid, somatropin, afamelanotid resolve). Lag (1991:1969) 1 § names no peptide and we do not apply it. Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": "2010-11",
    "last_verified": "2026-08-15"
  },
  {
    "slug": "tesofensine",
    "identifiers": {
      "unii": "BLH9UKX9V1",
      "cas": "195875-84-4",
      "verified": "2026-08-17"
    },
    "name": "Tesofensine",
    "aliases": [
      "NS 2330"
    ],
    "class": "Triple monoamine reuptake inhibitor, not a peptide",
    "eu_status": "unclear",
    "evidence_tier": "B",
    "legal_flags": {
      "de": {
        "status": "unclear",
        "basis": "Tesofensine does not appear in the DmMV 2023 Anlage, checked by full-text search across all headings on 2026-08-15. German medicines law under AMG §§ 73, 96, 97 is a separate question and is not established here.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38335 rows; semaglutid, tirzepatid, somatropin, afamelanotid resolve). Lag (1991:1969) 1 § names no peptide and we do not apply it. Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": null,
    "last_verified": "2026-08-15"
  },
  {
    "slug": "thymosin-alpha-1",
    "identifiers": {
      "unii": "W0B22ISQ1C",
      "cas": "62304-98-7",
      "verified": "2026-08-17"
    },
    "name": "Thymosin alpha 1",
    "aliases": [
      "Thymalfasin",
      "Zadaxin",
      "Talpha1"
    ],
    "class": "Thymic polypeptide, isolated and sequenced as an immunologically active thymic factor",
    "eu_status": "authorised",
    "evidence_tier": "B",
    "legal_flags": {
      "de": {
        "status": "unclear",
        "basis": "Thymosin alpha-1 does not appear in the DmMV 2023 Anlage, checked by full-text search on 2026-08-15; the Anlage names Thymosin-beta-4 und seine Derivate, a different peptide. German medicines law under AMG §§ 73, 96, 97 is a separate question and is not established here.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38335 rows; semaglutid, tirzepatid, somatropin, afamelanotid resolve). Lag (1991:1969) 1 § names no peptide and we do not apply it. Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": null,
    "last_verified": "2026-08-15"
  },
  {
    "slug": "vk2735",
    "name": "VK2735",
    "aliases": [
      "VK-2735"
    ],
    "class": "GIP and GLP-1 receptor dual agonist",
    "eu_status": "unclear",
    "evidence_tier": "B",
    "legal_flags": {
      "de": {
        "status": "unclear",
        "basis": "VK2735 does not appear in the DmMV 2023 Anlage, checked by full-text search across all headings on 2026-08-15. German medicines law under AMG §§ 73, 96, 97 is a separate question and is not established here.",
        "verified": "2026-08-17"
      },
      "se": {
        "status": "unclear",
        "basis": "Absent from Lakemedelsprodukter.xlsx (38335 rows; semaglutid, tirzepatid, somatropin, afamelanotid resolve). Lag (1991:1969) 1 § names no peptide and we do not apply it. Lakemedelslagen 2 kap. 1 § defines lakemedel without reference to authorisation, so absence does not settle medicines law.",
        "verified": "2026-08-17"
      }
    },
    "first_observed": null,
    "last_verified": "2026-08-15"
  }
]